KOSDAQ - Delayed Quote KRW

NIBEC Co., Ltd. (138610.KQ)

26,700.00
-500.00
(-1.84%)
At close: 3:30:23 PM GMT+9
Currency in KRW All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
23,739,200.83
24,550,141.59
15,703,946.24
21,670,439.54
13,625,370.97
Cost of Revenue
11,486,499.81
11,869,599.84
7,443,005.36
8,635,172.38
6,604,431.65
Gross Profit
12,252,701.02
12,680,541.75
8,260,940.88
13,035,267.16
7,020,939.32
Operating Expense
--
17,607,083
10,491,423
12,389,598
9,129,142
Operating Income
-2,068,155.43
-4,926,541.25
-2,230,482.12
645,669.16
-2,108,202.68
Net Non Operating Interest Income Expense
-1,428,296.54
-1,625,863.99
-2,356,247.58
-2,553,850.29
-1,760,532.23
Pretax Income
-11,088,166.67
-9,347,160.74
-6,181,225.44
-4,623,129.27
-5,653,060.80
Tax Provision
-20,656.57
-20,345.45
102,952.08
-857,266.64
86,706.14
Net Income Common Stockholders
-11,067,510.09
-9,326,815.28
-6,284,177.53
-3,765,862.62
-5,739,766.94
Basic EPS
-1.07k
--
-631.00
-379.00
-580.00
Diluted EPS
-1.07k
--
-631.00
-379.00
-580.00
Basic Average Shares
10,397.79
--
9,959.08
9,936.31
9,896.15
Diluted Average Shares
10,397.79
--
9,959.08
9,936.31
9,896.15
Total Operating Income as Reported
-6,465,065.50
-4,926,541.32
-2,230,481.87
645,669.18
-2,108,202.52
Rent Expense Supplemental
--
4,254
5,810
--
7,165
Total Expenses
25,807,356.26
29,476,682.84
17,934,428.36
21,024,770.38
15,733,573.65
Net Income from Continuing & Discontinued Operation
-11,067,510.09
-9,326,815.28
-6,284,177.53
-3,765,862.62
-5,739,766.94
Normalized Income
-7,052,261.21
-5,312,828.36
-4,797,861.49
-1,010,267.45
-4,027,347.44
Interest Income
--
417,237
312,550
104,029
66,774
Interest Expense
--
2,043,102
2,878,834
2,498,065
1,827,306
Net Interest Income
-1,428,296.54
-1,625,863.99
-2,356,247.58
-2,553,850.29
-1,760,532.23
EBIT
-4,445,672.92
-7,304,058.74
-3,302,391.44
-2,125,064.27
-3,825,754.80
EBITDA
-4,445,672.92
-4,057,190.74
75,064.56
976,468.73
-1,257,057.80
Reconciled Cost of Revenue
11,486,499.81
11,869,599.84
7,443,005.36
8,635,172.38
6,604,431.65
Reconciled Depreciation
--
3,246,868
3,377,456
3,101,533
2,568,697
Net Income from Continuing Operation Net Minority Interest
-11,067,510.09
-9,326,815.28
-6,284,177.53
-3,765,862.62
-5,739,766.94
Total Unusual Items Excluding Goodwill
-4,022,743
-4,022,743
-1,955,679
-3,382,883
-2,283,226
Total Unusual Items
-4,022,743
-4,022,743
-1,955,679
-3,382,883
-2,283,226
Normalized EBITDA
-422,929.92
-34,447.74
2,030,743.56
4,359,351.73
1,026,168.20
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-7,494.12
-8,756.08
-469,362.96
-627,287.83
-570,806.50
12/31/2021 - 7/13/2011

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

688105.SS Nanjing Vazyme Biotech Co., Ltd
23.24
+5.49%
 
600161.SS TIANTAN BIO
20.21
+0.30%
 
688331.SS RemeGen Co., Ltd.
61.59
+0.97%
 
688278.SS Xiamen Amoytop Biotech Co., Ltd.
73.56
-0.11%
 
688578.SS Shanghai Allist Pharmaceuticals Co., Ltd.
96.00
+1.80%
 
688382.SS InventisBio Co., Limited
32.80
+9.12%
 
688428.SS InnoCare Pharma Limited
27.00
+9.93%
 
688180.SS Shanghai Junshi Biosciences Co., Ltd.
33.87
+2.36%
 
GYRE Gyre Therapeutics, Inc.
8.41
+5.52%
 
CAMX.ST Camurus AB (publ)
666.00
+4.31%